Offering a pre-clinical drug discovery platform designed to treat inflammatory diseases, the Neutrolis platform focuses on researching new potential treatment options to neutralize excessive neutrophilic inflammation, enabling patients to get therapies to regulate the inflammatory process. Principals of the firm are advancing their therapies targeted at Neutrophil Extracellular Traps (NETs) - fundamental arm of the immune system that play an important role in chronic and acute diseases. With NETs representing one of the most important immunology discoveries in the past 20 years, to date no therapy has been offered that can effectively targets and remove NETs. Founded by two leaders in the NETs field and supported by a seasoned biotech executive with a track record of successful M&A, Nutrolisâ pipeline includes NTR-441 and NTR-10 - that effectively removes NETs and halts their pathologic effects on end-organs. The firm has a strong patent portfolio for new molecular entity and method of use with their lead molecule - NTR-441 - having been slated to enter clinical trials in 2021
